Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.5600 +0.2300 (+17.29%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.5800 +0.0200 (+1.28%) 19:51 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.3800
Day High
1.5800
Open 1.3800
Previous Close 1.3300 1.3300
Volume 3,535,100 3,535,100
Avg Vol 2,131,000 2,131,000
Stochastic %K 81.10% 81.10%
Weighted Alpha -71.79 -71.79
5-Day Change +0.2400 (+18.18%) +0.2400 (+18.18%)
52-Week Range 0.9100 - 6.6900 0.9100 - 6.6900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,334
  • Shares Outstanding, K 83,710
  • Annual Sales, $ 32,310 K
  • Annual Income, $ -237,090 K
  • EBIT $ -239 M
  • EBITDA $ -239 M
  • 60-Month Beta 2.16
  • Price/Sales 3.32
  • Price/Cash Flow N/A
  • Price/Book 0.79

Options Overview Details

View History
  • Implied Volatility 136.21% ( -10.67%)
  • Historical Volatility 109.28%
  • IV Percentile 82%
  • IV Rank 55.51%
  • IV High 216.03% on 02/19/25
  • IV Low 36.62% on 05/30/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 2,641
  • Volume Avg (30-Day) 869
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 40,447
  • Open Int (30-Day) 39,029

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.51
  • Number of Estimates 5
  • High Estimate -0.41
  • Low Estimate -0.63
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +32.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9100 +71.43%
on 04/07/25
Period Open: 1.3100
1.5800 -1.27%
on 04/22/25
+0.2500 (+19.08%)
since 03/21/25
3-Month
0.9100 +71.43%
on 04/07/25
Period Open: 1.3400
3.2999 -52.73%
on 02/19/25
+0.2200 (+16.42%)
since 01/22/25
52-Week
0.9100 +71.43%
on 04/07/25
Period Open: 5.6000
6.6900 -76.68%
on 05/15/24
-4.0400 (-72.14%)
since 04/22/24

Most Recent Stories

More News
Editas Medicine Announces Chief Financial Officer Transition

EDIT : 1.5600 (+17.29%)
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential

The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.

IBB : 120.43 (+2.72%)
EDIT : 1.5600 (+17.29%)
VTI : 259.03 (+2.55%)
IWM : 187.47 (+2.59%)
Editas: Q4 Earnings Snapshot

Editas: Q4 Earnings Snapshot

EDIT : 1.5600 (+17.29%)
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

EDIT : 1.5600 (+17.29%)
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

EDIT : 1.5600 (+17.29%)
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

EDIT : 1.5600 (+17.29%)
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EDIT : 1.5600 (+17.29%)
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive...

CTMX : 0.7361 (-1.84%)
CSTL : 21.98 (+3.97%)
EDIT : 1.5600 (+17.29%)
SPRO : 0.7322 (+0.99%)
Editas Medicine Advances In Vivo CRISPR-Edited Medicines, Announces Workforce Reduction and Strategic Transition

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases.Quiver AI SummaryEditas Medicine, Inc. has announced...

EDIT : 1.5600 (+17.29%)
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

EDIT : 1.5600 (+17.29%)

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 1.8333
2nd Resistance Point 1.7067
1st Resistance Point 1.6333
Last Price 1.5600
1st Support Level 1.4333
2nd Support Level 1.3067
3rd Support Level 1.2333

See More

52-Week High 6.6900
Fibonacci 61.8% 4.4820
Fibonacci 50% 3.8000
Fibonacci 38.2% 3.1180
Last Price 1.5600
52-Week Low 0.9100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro